Better Protein Design: Faster and More Precise

SCICS (pronounced 'saiks') simultaneously measures protein structures and protein-protein interactions using cutting-edge mass spectrometry, accelerating the discovery of proteins that improve human well-being. We are the only company in the world offering dual-platform technologies for both protein structure and protein-protein interaction discovery. Our breakthrough AI-driven protein design technology, combined with precision validation through mass spectrometry, truly sets us apart.

Our Approach

Protein-protein interactions govern all of biology and are crucial for understanding and combating disease.
However, a lack of abundant and high-quality protein-protein interaction data limits our understanding and ability to treat cancers, infectious diseases, neurological diseases, and more.
SCICS generates the high-throughput data needed to discover rare and effective antibodies, identify degradable neo-substrates, engineer protein interfaces, and fuel predictive deep learning models to further accelerate the discovery and optimization of high-impact peptide drugs.

Strategic Vision and Expansion Opportunities for Our Company

A. Peptides are known as the smallest units possessing protein functionality, composed of 2-50 amino acids—the fundamental constituents of proteins. Peptide drugs stand out for their biocompatibility, specificity in vivo, and their capacity to exert significant pharmacological effects and activities at minimal doses, all while maintaining a low side-effect profile.

B. Despite their advantages, peptide drugs face challenges such as poor cell membrane permeability, complications with oral administration, and rapid breakdown by enzymes. However, recent advancements in peptide design technology, bolstered by deep learning algorithms, are paving the way to overcome these limitations.

C. In the contemporary medical landscape, peptide drugs are emerging as groundbreaking treatments for metabolic disorders like obesity and diabetes. Their application as therapeutics and biomaterials spans a wide array of diseases, showcasing their versatility. The development of peptide therapeutics is characterized by high selectivity, efficacy, and safety. Recent research has focused on multifunctional and cell-penetrating peptides, as well as peptide drug complexes, highlighting the sector's innovative progress.

D. The emergence of biosimilars, following the expiration of patents, is poised to significantly propel the expansion of the peptide therapeutics market. Furthermore, the escalating demand for targeted therapies and personalized medicine is set to further drive the growth of this sector.

E. Within the realm of protein structure-based peptide drug development, no company globally boasts dual platform technologies validated by both artificial intelligence prediction and precision analysis experimentation. Our ambition is to carve out a niche in the advanced peptide drug discovery market by independently harnessing these cutting-edge technologies.

Value Proposition for Customers

A. Our objective is to offer a peptide drug development platform that integrates artificial intelligence predictions with structural protein experimentation. AI's capability to swiftly sift through vast quantities of biological data allows for the rapid identification of new drug candidates. By amalgamating insights from structural protein analysis with AI models, we enable expedited and precise drug discovery processes.

B. Peptide drugs are exceptionally well-suited for the creation of personalized medicine, thanks to their structural and functional diversity. AI's analysis of patients' genetic and biological data facilitates the design of tailor-made peptide drugs. Furthermore, it enables the innovation of peptides with novel structures and functions, thereby broadening the spectrum of new drug candidates.

C. Employing structural proteomics offers a deeper comprehension of the biological targets peptide drugs may interact with, minimizing the risk of off-target effects that could lead to adverse reactions. This approach underscores our commitment to developing highly selective and safe therapeutic options, aligning with the principles of precision medicine.